

- [Journal of Clinical Oncology](#) >
- [List of Issues](#) >
- [Volume 37, Issue 15_suppl](#) >

MELANOMA/SKIN CANCERS

- [Rights & Permissions](#)

COMPANION ARTICLES

No companion articles

ARTICLE CITATION

DOI: 10.1200/JCO.2019.37.15_suppl.9507 *Journal of Clinical Oncology* - published online before print May 26, 2019

Five-year analysis on the long-term effects of dabrafenib plus trametinib (D + T) in patients with *BRAF* V600–mutant unresectable or metastatic melanoma.

[Paul D. Nathan](#), [Caroline Robert](#), [Jean Jacques Grob](#), [Daniil Stroyakovskiy](#), [Boguslawa Karaszewska](#), [Axel Hauschild](#), [Eugeny Levchenko](#), [Vanna Chiarion Sileni](#), [Jacob Schachter](#), [Claus Garbe](#), [Igor Bondarenko](#), [Michael A. Davies](#), [Antoni Ribas](#), [Keith Flaherty](#), [Paul Burgess](#), [Monique Tan](#), [Eduard Gasal](#), [Dirk Schadendorf](#), [Georgina V. Long](#) Mount Vernon Cancer Centre, Northwood, United Kingdom; Paris-Sud University, Gustave Roussy, Villejuif Cedex, France; Aix-Marseille University, Marseille, France; Moscow City Oncology Hospital, Moscow, Russian Federation; Przychodnia Lekarska KOMED, Konin, Poland; University Hospital Schleswig-Holstein, Kiel, Germany; Petrov Research Institute of Oncology, St. Petersburg, Russia; Melanoma Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy; Ella Lemelbaum Institute for Immuno-Oncology and Melanoma, Sheba Medical Center, Tel-Hashomer, and Sackler Medical School, Tel-Aviv University, Tel-Aviv, Israel; Department of Dermatology, University of Tübingen, Tübingen, Germany; Dnepropetrovsk State Medical Academy, Dnepropetrovsk, Ukraine; The University of Texas MD Anderson Cancer Center, Houston, TX; University of California, Los Angeles, Los Angeles, CA; Dana-Farber Cancer Institute/Harvard Medical School and Massachusetts General Hospital, Boston, MA; Novartis Pharma AG, Basel, Switzerland; Novartis Pharmaceuticals Corporation, East Hanover, NJ; Department of Dermatology, University Hospital Essen, Essen, Germany; Melanoma Institute Australia, The University of Sydney, and Royal North Shore and Mater Hospitals, Sydney, Australia

Background: First-line treatment with D+T demonstrated prolonged progression-free survival (PFS) and overall survival (OS) in patients with *BRAF* V600–mutant unresectable or metastatic melanoma. With 5 years of follow-up, we report survival and describe characteristics of patients in the phase 3 COMBI-d and COMBI-v trials with long-term benefit. **Methods:** Pooled 5-year landmark data for patients treated with D+T in the phase 3 COMBI-d (NCT01584648) and COMBI-v (NCT01597908) trials were analyzed. The trials enrolled patients with previously untreated *BRAF* V600E/K–mutant unresectable or metastatic melanoma. Patients received D 150 mg twice daily plus T 2 mg once daily vs either D + placebo (COMBI-d) or vemurafenib (COMBI-v). The primary endpoints were PFS in COMBI-d and OS in COMBI-v. **Results:** The pooled population included 563 patients who received D+T (COMBI-d, n = 211; COMBI-v, n = 352). Four- and 5-year PFS and OS rates were similar, suggesting a stabilization (4- and 5-year PFS, 21% [95% CI, 17%-24%] and 19% [95% CI, 15%-22%, respectively]; 4- and 5-year OS, 37% [95% CI, 33%-42%] and 34% [95% CI, 30%-38%], respectively). In patients with normal baseline lactate dehydrogenase (LDH) levels the 5-year PFS rate was 25% vs 8% in patients with elevated baseline LDH levels. Similarly, the 5-year OS rate was considerably higher in patients with normal baseline LDH levels vs those with elevated LDH levels at baseline (43% vs 16%). Among patients with normal baseline LDH levels and < 3 organ sites with metastases, the 5-year PFS and OS rates were 31% and 55%, respectively. In addition, exploratory analyses will be performed to characterize subgroup(s) of patients most likely to experience long-term benefit. Of 299 patients who received subsequent anticancer therapy following treatment with D+T, 151 (51%) received an anti–CTLA-4 therapy and 102 (34%) received an anti–PD-1 therapy. The safety profile of D+T was as previously reported, and no new safety signals were observed. No treatment-related deaths were reported. **Conclusions:** First-line treatment with D+T leads to durable long-term benefit in many patients with *BRAF* V600–mutant unresectable or metastatic melanoma. **Clinical trial information:** [NCT01584648](https://clinicaltrials.gov/ct2/show/study/NCT01584648); [NCT01597908](https://clinicaltrials.gov/ct2/show/study/NCT01597908).